■斯德哥尔摩的Capio前列腺癌中心(CapioPCC),瑞典,采用全面的诊断方法,利用前列腺特异性抗原(PSA),Stockholm3和磁共振成像(MRI)用于前列腺癌风险评估,然后对高危病例进行有针对性的系统性活检.
本研究旨在阐明CapioS:tGöran医院用于前列腺癌诊断的CapioPCC模型的临床过程和实际结果。
■在2018年至2022年之间,有12.406名45-75岁的男性接受了前列腺癌检测,坚持CapioPCC的结构化诊断协议。
■我们提供了对CapioPCC模型的全面描述,并介绍了其实现的结果,包括PSA的评估,Stockholm3核磁共振扫描,和活检。在CapioPCC获得的诊断结果与在瑞典其他地区获得的诊断结果之间进行了比较分析。
■参与者年龄中位数为61岁(四分位距[IQR]:55-67),PSA水平为1.6ng/ml(IQR:0.8-3.3),Stockholm3评分为4(IQR:3-11)。在接受活检的1064名男性(8.6%)中,611例(57%的活检)被诊断为国际泌尿外科病理学学会≥2级癌症。值得注意的是,采用Stockholm3≥15的切断值进行活检,代替PSA≥3ng/ml,活检建议减少了43%。对于PSA水平在1.5和2.9ng/ml之间的男性,360(12%)的Stockholm3评分≥15,其中72(活检的56%)被诊断为具有临床意义的前列腺癌。与瑞典国家前列腺癌检测数据的比较分析表明,CapioPCC模型(相对于瑞典)揭示了14%(相对于25%)低风险的分布,59%(比42%)中等风险,和26%(vs30%)高风险和晚期癌症。
■这项研究强调了CapioPCC协议驱动诊断过程的有效性,与瑞典的标准前列腺癌治疗相比,能够更早地检测中危前列腺癌,并减少对MRI评估的需要。
■在Capio前列腺癌中心,一种结合前列腺特异性抗原的新诊断方法,Stockholm3磁共振成像,斯德哥尔摩已经实施了针对性的活检,以加强前列腺癌的检测和诊断,瑞典。
UNASSIGNED: The Capio Prostate Cancer Center (Capio PCC) in Stockholm, Sweden, adopts a comprehensive diagnostic approach, utilizing prostate-specific antigen (PSA), Stockholm3, and magnetic resonance imaging (MRI) for prostate cancer risk assessment, followed by targeted and systematic biopsies for high-risk cases.
UNASSIGNED: This study aims to elucidate the clinical process and real-world outcomes of the Capio PCC model for prostate cancer diagnosis at Capio S:t Göran Hospital.
UNASSIGNED: Between 2018 and 2022, a cohort of 12 406 men aged 45-75 yr underwent prostate cancer testing, adhering to Capio PCC\'s structured diagnostic protocol.
UNASSIGNED: We provide a comprehensive description of the Capio PCC model and present results from its implementation, including assessments of PSA, Stockholm3, MRI scans, and biopsies. A comparative analysis is conducted between the diagnostic outcomes obtained at Capio PCC and those obtained at other regions in Sweden.
UNASSIGNED: The median participant age was 61 yr (interquartile range [IQR]: 55-67), with PSA levels at 1.6 ng/ml (IQR: 0.8-3.3) and Stockholm3 scores at 4 (IQR: 3-11). Among 1064 men (8.6%) undergoing biopsies, 611 (57% of biopsied) were diagnosed with International Society of Urological Pathology grade ≥ 2 cancer. Notably, employing a Stockholm3 ≥ 15 cutoff for biopsy, in lieu of PSA ≥ 3 ng/ml, reduced biopsy recommendations by 43%. For men with PSA levels between 1.5 and 2.9 ng/ml, 360 (12%) exhibited Stockholm3 scores of ≥ 15, with 72 (56% of biopsied) diagnosed with clinically significant prostate cancer. A comparative analysis with national Swedish prostate cancer detection data indicated that the Capio PCC model (vs Sweden) revealed a distribution of 14% (vs 25%) low-risk, 59% (vs 42%) intermediate-risk, and 26% (vs 30%) high-risk and advanced cancers.
UNASSIGNED: This study underscores the effectiveness of the protocol-driven diagnostic process at Capio PCC, enabling earlier detection of intermediate-risk prostate cancer and reducing the need for MRI assessments compared with standard prostate cancer care in Sweden.
UNASSIGNED: At the Capio Prostate Cancer Center, a novel diagnostic approach incorporating prostate-specific antigen, Stockholm3, magnetic resonance imaging, and targeted biopsies has been implemented to enhance prostate cancer testing and diagnosis in Stockholm, Sweden.